Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19
March 02, 2020 07:50 ET
|
Mateon Therapeutics
Company has formed a new Division, led by Dr. Cyril Empig, to develop a multi-modal approach to treating the COVID-19 and future emergent zoonotic outbreaks Rapid response platform based on the...
Mateon Therapeutics Team Publishes a New Peer-Reviewed Oncology Article on the Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients With Relapsed Acute Myeloid Leukemia
December 27, 2019 08:30 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD. PhD,...
Mateon Therapeutics Announces Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients with Relapsed Acute Myeloid Leukemia
December 23, 2019 14:30 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN), dedicated to the development of innovative treatments for cancer, today announced that the...
EdgePoint announces collaboration with iBio CDMO to implement AI/Blockchain driven TrustPoint Vision Technology in its Texas cGMP facility
December 23, 2019 09:30 ET
|
Mateon Therapeutics
TrustPoint has the potential to improve documentation processes by automating data documentation and verification leading to improved data integrity and reduced operating expenses Collaboration...
Steven King Named as Prospective CEO of EdgePoint AI
December 11, 2019 08:30 ET
|
Mateon Therapeutics
Brings over 20 years of experience in drug development and pharmaceutical manufacturing, as well as Nasdaq listed public company experience EdgePoint AI is to commercialize TrustPoint AI artificial...
Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen
December 02, 2019 09:15 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN, “Mateon”) dedicated to the development of...
Mateon Therapeutics to Present New and Updated Data for OT101 (Trabedersen) Activity Against Brain Tumors at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
November 18, 2019 09:25 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative...
Mateon completes its acquisition of PointR Data Inc.
November 04, 2019 10:30 ET
|
Mateon Therapeutics
SANTA CLARA, Calif. and AGOURA HILLS, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (‘Mateon”) announced today that they have completed their acquisition of...
New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor
October 23, 2019 13:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative...
FDA Grants Pediatric Disease Designation for Mateon’s OT101
September 23, 2019 09:00 ET
|
Mateon Therapeutics
For treatment of diffuse intrinsic pontine glioma (DIPG), a difficult to treat form of childhood brain tumor AGOURA HILLS, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc....